Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617942

— · C

bf3cd235-7660-5c05-99ae-1e112e919f59

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
  • PROTEIN_SECRETION+0.350
  • ANDROGEN_RESPONSE+0.300
  • ANGIOGENESIS+0.290
  • TGF_BETA_SIGNALING+0.290
  • CHOLESTEROL_HOMEOSTASIS+0.280
  • OXIDATIVE_PHOSPHORYLATION+0.240
  • COAGULATION+0.220
  • HYPOXIA+0.210
  • ESTROGEN_RESPONSE_EARLY+0.190

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.500
  • ALLOGRAFT_REJECTION-0.360
  • IL6_JAK_STAT3_SIGNALING-0.350
  • PANCREAS_BETA_CELLS-0.190
  • IL2_STAT5_SIGNALING-0.170
  • KRAS_SIGNALING_DN-0.160
  • INFLAMMATORY_RESPONSE-0.150
  • PEROXISOME-0.130
  • DNA_REPAIR-0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120020076.Her2HRpos
breast-umap@18
—C0.806
2TCGA-E2-A15L-01A-11R-A12D-07
breast-umap@18
—B0.789
3BSR_19_0079_A1_S53
breast-umap@18
—B0.778
4SRR25617938
breast-umap@18
—B0.775
5MBCProject_1181_T1_RNA
breast-umap@18
—B0.764
6TCGA-CR-5247-01A-01R-2016-07
head-neck@1
——0.762
7R185
bladder-landscape@3
——0.757
8TCGA-75-7027-01A-11R-1949-07
lung-landscapes@6
—cohortA40.754
9TCGA-33-4547-01A-01R-1201-07
lung-landscapes@6
—cohortSQ10.736
10SRR8518326
breast-umap@18
—E0.733

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.440Inavolisib— uncovered
PROTEIN_SECRETION0.350Remibrutinib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
ANGIOGENESIS0.290Remibrutinib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.280Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.240Remibrutinib— uncovered
COAGULATION0.220Binimetinib— uncovered
HYPOXIA0.210Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.190Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.160Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.150Idelalisib— uncovered
G2M_CHECKPOINT0.150Inavolisib— uncovered
NOTCH_SIGNALING0.140Inavolisib— uncovered
APICAL_JUNCTION0.130Inavolisib— uncovered
HEDGEHOG_SIGNALING0.130Inavolisib— uncovered
GLYCOLYSIS0.110Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
MTORC1_SIGNALING0.090Inavolisib— uncovered
APICAL_SURFACE0.060Temsirolimus— uncovered